Investment & M&A transaction comps
Vitamins Investment & M&A Transaction Comps
Explore investment and M&A transactions tagged vitamins. Compare companies, buyers, dates and available valuation multiples, with reported, estimated or rumored figures clearly labelled in each comp.
Coverage includes published FundComb transactions carrying this tag. Each comp preserves its own source notes and valuation basis.
- Reviewed transactions
- 26
- With value data
- 22
- With revenue multiples
- 17
- Transaction years
- 2012–2026
Sortable transaction comps
Vitamins transaction table
Rows with reported value
21 / 25
Acquisition EV, USD
USD 48B
Investment EV, USD
-
Median EV / revenue
3.6x
Selected comparison set
Saved in this browser only. Nothing is written to FundComb data.
Choose transactions from the table to build a quick comparison set.
25 shown of 26 matching transactions. Click any transaction row for more detail.
Values are 100% enterprise values. Multiples divide EV by full-company revenue or EBITDA. Reported prices are assumed to be EV; explicit partial-stake prices are grossed up as estimates. Amounts paid are tracked separately, and a financing without a reported valuation shows its amount raised, not an EV.
| Select for comparison | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Twinlab Control | 2026-09-02 | cbdMD | Undisclosed Consideration | Undisclosed | - | - | - | Confirmed 4 sources | ||
| Nestlé Holistic Health Platform Control | 2026-09-01 | Yellow Wood Partners | USD 1.0B Consideration | 1,000 | - | - | - | Confirmed 2 sources | ||
| Jamieson Wellness Control (100%) | 2026-08-06 | Kirin Holdings Company | CAD 2.5B Enterprise Value | 1,785 | - | - | Canada | Confirmed 1 source | ||
| Thorne Control | 2026-08-04 | Procter & Gamble | USD 3.8B Consideration | 3,800 | 7.6x | - | United States | Estimated 3 sources | ||
| Vitabiotics Control | 2026-07-24 | Bain Capital | USD 1.0B Estimated Enterprise Value | 1,038 | - | - | United Kingdom | Confirmed 3 sources | ||
| Opella Control (50%) | 2024-10-21 | Clayton, Dubilier & Rice | EUR 16B Enterprise Value | 17,365 | 3.1x | 14.0x | France, United States & Global | Confirmed 1 source | ||
| Sunday Natural Control (55%) | 2024-01-15 | CVC Capital Partners | EUR 800M Enterprise Value | 875 | 8.0x | 16.0x | Germany | Estimated 1 source | ||
| Blackmores Control (100%) | 2023-04-26 | Kirin | USD 1.2B Enterprise Value | 1,241 | 2.9x | 23.1x | Australia | Estimated 3 sources | ||
| 2021-04-30 | Nestlé | USD 5.8B Consideration | 5,750 | 3.1x | 16.8x | - | Confirmed 2 sources | |||
| Onnit Labs, Inc. Control (100%) | 2021-04-26 | Unilever | Undisclosed | Undisclosed | - | - | United States | Estimated 1 source | ||
| Smarty Pants Control (100%) | 2020-11-25 | Unilever | Undisclosed | Undisclosed | 4.0x | - | - | Confirmed 2 sources | ||
| Natrol LLC Control (100%) | 2020-10-26 | New Mountain Capital | USD 550M Consideration | 550 | 3.5x | - | United States | Confirmed 1 source | ||
| Jennewein Biotechnologie GmbH Control (100%) | 2020-09-22 | Chr. Hansen Holding A/S | EUR 310M Enterprise Value | 367 | 6.2x | - | Germany & Global | Confirmed 1 source | ||
| Care/of Control | 2020-08-31 | Bayer | USD 225M | 225 | - | - | United States | Confirmed 1 source | ||
| PrecisionBiotics Group Limited Control (100%) | 2020-06-25 | Novozymes | DKK 600M Enterprise Value | 90 | 6.0x | - | Cork, Ireland | Estimated 1 source | ||
| Pfizer Consumer Healthcare Control (68%) | 2018-12-19 | GlaxoSmithKline (GSK-Pfizer consumer joint venture) | Undisclosed | Undisclosed | - | - | United States & Global | Estimated 1 source | ||
| GSK Consumer Healthcare India (Horlicks) Control (100%) | 2018-12-03 | Hindustan Unilever and Unilever | EUR 5.3B Consideration | 5,999 | 9.6x | - | India, Bangladesh & Asian Markets | Confirmed 1 source | ||
| Nutranext Control | 2018-03-12 | Clorox | USD 700M Consideration | 700 | 3.5x | 14.0x | - | Estimated 1 source | ||
| Life-Space Group Control (100%) | 2018-01-31 | BY-HEALTH Co., Ltd. | AUD 670M Enterprise Value | 543 | - | - | Australia | Estimated 1 source | ||
| Atrium Innovations Control | 2017-12-05 | Nestlé | USD 2.3B Consideration | 2,300 | 3.3x | 19.0x | - | Confirmed 1 source | ||
| Vitaco Control | 2016-08-01 | Primavera Capital | AUD 345M Enterprise Value | 261 | 1.5x | 14.7x | Australia/New Zealand | Confirmed 1 source | ||
| Nutraceutix assets Control (100%) | 2016-06-06 | Probi AB | USD 105M Enterprise Value | 105 | 3.1x | 13.1x | United States | Confirmed 1 source | ||
| Swisse Control (83%) | 2015-09-17 | Biostime | AUD 1.7B Enterprise Value | 1,197 | 3.6x | 10.2x | Australia | Confirmed 3 sources | ||
| Atrium Innovations Inc. Control | 2013-11-29 | Permira Advisers Ltd. | USD 1.0B Enterprise Value | 1,036 | - | 10.8x | Canada | Estimated 3 sources | ||
| Schiff Nutrition Control | 2012-11-22 | Reckitt Benckiser | USD 1.4B Enterprise Value | 1,400 | 4.2x | 19.1x | - | Confirmed 3 sources |
Explore related tags
Continue to the full transaction history for each tag.
Explore buyers & investors
Source coverage varies by transaction. Announced deals, minority investments and capital raises retain their own labels; an investment amount is separate from enterprise value. Read the methodology.